We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When rumours first started rumbling about a mega-merger between Bayer and Monsanto, one of the major question marks was on how this would impact the pharmaceutical side of Bayer’s business.